Ozcan Uzun

Ozcan Uzun

Auto-generated profile, based on publicly available information

Ozcan Uzun

Yalova Research and Training Hospital, Yalova, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
SSSerife Solmaz
Serife Solmaz
OUOzcan Uzun
Ozcan Uzun
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
FDFatih Demirkan
Fatih Demirkan
MOMehmet Ali Ozcan
Mehmet Ali Ozcan
IAInci Alacacıoglu
Inci Alacacıoglu

5 December 2022 in Journal of Chemotherapy
Verified
Journal Article
Closed access
BEBişar Ergün
Bişar Ergün
FEFethiye Esenkaya
Fethiye Esenkaya
MKMurat Küçük
Murat Küçük
MYMehmet Nuri Yakar
Mehmet Nuri Yakar
ÖUÖzcan Uzun
Özcan Uzun
AGAli Necati Gökmen
Ali Necati Gökmen
In this retrospective cohort study, we aimed to evaluate the incidence, risk factors and outcomes of amikacin-induced acute kidney injury (AKI) in critically ill patients with sepsis. A total of 311 patients were included in the study. Of them, 83 (26.7%) had amikacin-induced AKI. In model 1, the multivariable analysis demonstrated concurrent use of colistin (OR 25.51, 95%CI 6.99-93.05, p< 0.001), presence of septic shock during amikacin treatment (OR 4.22, 95%CI 1.76-10.11, p=0.001), and Charlson Comorbidity Index (OR 1.14, 95%CI 1.02-1.28, p=0.025) as factors independently associated with an increased risk of amikacin-induced AKI. In model 2, the multivariable analysis demonstrated concurrent use of at least one nephrotoxic agent (OR 1.95, 95%CI 1.10-3.45; p=0.022), presence of septic shock during amikacin treatment (OR 3.48, 95%CI 1.61-7.53; p=0.002), and Charlson Comorbidity Index (OR 1.12, 95%CI 1.01-1.26; p=0.037) as factors independently associated with an increased risk of amikacin-induced AKI. In conclusion, before amikacin administration, the risk of AKI should be considered, especially in patients with multiple complicated comorbid diseases, septic shock, and those receiving colistin therapy.

28 March 2023 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
FYFiliz Yıldırım
Filiz Yıldırım
OUOzcan Uzun
Ozcan Uzun
GNGuler Nasuhbeyoglu
Guler Nasuhbeyoglu
ANAslihan Narlioglu
Aslihan Narlioglu
YBYelda Deligoz Bildaci
Yelda Deligoz Bildaci
SDSerpil Müge Değer
Serpil Müge Değer

7 August 2025 in Nefrología (English Edition)
Verified
Journal Article
Open access
OUOzcan Uzun
Ozcan Uzun
CHCihan Heybeli
Cihan Heybeli
FKFatma Sema Anar Kutlu
Fatma Sema Anar Kutlu
EAEvrim Atmaca
Evrim Atmaca
FYFiliz Yıldırım
Filiz Yıldırım
SSSulen Sarioglu
Sulen Sarioglu
To determine the possible relationship between macrophage phenotypes and the progression of kidney disease in patients with lupus nephritis (LN). Using immunohistochemistry, CD68+ and CD163+ cells were counted per glomerulus and per high-power field in the tubulointerstitium. Progression was defined as a doubling of the serum creatinine level and/or progression to end-stage kidney disease. Among the 21 patients, 52% had class III or IV LN. During the median follow-up of 88 months, 5 (23.8%) patients experienced progression. In terms of clinical and pathological markers, the only significant difference between progressors and nonprogressors was the number of interstitial CD163+ cells (median 4 versus 2.4, respectively; p=0.025). A cutoff value of 2.7 for the mean number of CD163+ cells in the interstitium yielded a sensitivity of 80% and specificity of 75% for progression. The estimated median time to progression among patients with ≥2.7 CD163+ cells was shorter (median 136 versus 202 months, p=0.023). A greater number of CD163+ cells in the kidney interstitium was associated with the progression of kidney disease (HR 2.88, 95% CI 1.22-6.80; p=0.016). Class III-IV LN was associated with a higher median number of glomerular CD163+ cells (OR 1.96, 95% CI 1.1-3.49, p=0.023). Endocapillary hypercellularity and extracapillary proliferation were associated with greater number of CD163+ cells in the glomerular area. Among patients with class III-IV LN, the number of interstitial CD68+ cells was greater in those who experienced progression of kidney disease (p=0.012). A greater number of CD163+ cells in the kidney interstitium was associated with the progression of kidney disease in patients with LN, while a greater number of CD68+ cells in the interstitium was associated with progression in the subgroup of patients with class III-IV LN.

1 January 2021 in Turkish Journal of Pathology
Verified
Journal Article
Open access
CHCihan Heybeli
Cihan Heybeli
BYBerna Demir Yuksel
Berna Demir Yuksel
MUMehtat Unlu
Mehtat Unlu
MOMehmet Asi Oktan
Mehmet Asi Oktan
HAHayri Ustun Arda
Hayri Ustun Arda
SSSulen Sarioglu
Sulen Sarioglu
Objective: Granulomatous interstitial nephritis is a rare finding, and etiology differs by geography. We aimed to investigate the distribution of causes of granuloma/granulomata in the kidney and renal survival of these patients in a tertiary care hospital in Western Turkey.

5 May 2025 in Nefrología
Verified
Journal Article
Open access
OUOzcan Uzun
Ozcan Uzun
CHCihan Heybeli
Cihan Heybeli
FKFatma Sema Anar Kutlu
Fatma Sema Anar Kutlu
EAEvrim Ataca
Evrim Ataca
FYFiliz Yıldırım
Filiz Yıldırım
SSSulen Sarioglu
Sulen Sarioglu